Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APENNASDAQ:ATRCNASDAQ:LMATNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPENApollo Endosurgery$9.94$3.49▼$10.30$579.72M2.311.43 million shs1.66 million shsATRCAtriCure$32.33-1.7%$32.51$20.20▼$43.11$1.60B1.59615,296 shs52,855 shsLMATLeMaitre Vascular$82.99+0.7%$83.82$71.42▼$109.58$1.87B0.83169,980 shs27,028 shsNVCRNovoCure$17.15+0.3%$17.61$14.17▼$34.13$1.91B0.741.18 million shs121,253 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPENApollo Endosurgery0.00%0.00%0.00%0.00%0.00%ATRCAtriCure+1.89%+4.02%-3.27%+3.30%+42.96%LMATLeMaitre Vascular-2.53%+0.87%-0.34%-0.78%+0.62%NVCRNovoCure-1.33%+1.79%-10.84%-9.33%-5.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPENApollo EndosurgeryN/AN/AN/AN/AN/AN/AN/AN/AATRCAtriCure2.9571 of 5 stars3.53.00.00.02.52.50.6LMATLeMaitre Vascular2.6118 of 5 stars2.22.03.30.01.72.51.3NVCRNovoCure3.8742 of 5 stars3.31.00.04.53.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPENApollo Endosurgery 0.00N/AN/AN/AATRCAtriCure 3.00Buy$50.6756.71% UpsideLMATLeMaitre Vascular 2.33Hold$97.8317.89% UpsideNVCRNovoCure 2.67Moderate Buy$32.8391.47% UpsideCurrent Analyst Ratings BreakdownLatest APEN, NVCR, LMAT, and ATRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025ATRCAtriCureJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$60.00 ➝ $60.004/30/2025ATRCAtriCureUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $58.004/30/2025ATRCAtriCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.003/28/2025ATRCAtriCureCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $52.003/27/2025ATRCAtriCureBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/27/2025ATRCAtriCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$51.00 ➝ $46.003/27/2025ATRCAtriCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPENApollo Endosurgery$76.86M0.00N/AN/A$0.69 per share0.00ATRCAtriCure$465.31M3.44N/AN/A$9.46 per share3.42LMATLeMaitre Vascular$219.86M8.53$2.34 per share35.39$15.00 per share5.53NVCRNovoCure$605.22M3.16N/AN/A$3.33 per share5.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPENApollo Endosurgery-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/AATRCAtriCure-$44.70M-$0.81N/AN/AN/A-7.95%-5.68%-4.34%7/29/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9841.9138.242.2319.96%13.53%9.78%7/30/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)Latest APEN, NVCR, LMAT, and ATRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/29/2025Q1 2025ATRCAtriCure-$0.25-$0.14+$0.11-$0.14$122.92 million$123.62 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPENApollo EndosurgeryN/AN/AN/AN/AN/AATRCAtriCureN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.96%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest APEN, NVCR, LMAT, and ATRC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPENApollo Endosurgery1.042.351.89ATRCAtriCure0.164.112.88LMATLeMaitre Vascular0.4816.4913.83NVCRNovoCure0.271.471.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPENApollo Endosurgery76.01%ATRCAtriCure99.11%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipAPENApollo Endosurgery17.30%ATRCAtriCure3.50%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPENApollo Endosurgery20257.97 million47.94 millionNot OptionableATRCAtriCure1,30049.51 million47.77 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableAPEN, NVCR, LMAT, and ATRC HeadlinesRecent News About These CompaniesSG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)June 23, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?June 18, 2025 | marketbeat.comWhat Makes NovoCure (NVCR) a New Buy StockJune 18, 2025 | zacks.comGAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)June 17, 2025 | marketbeat.comSimon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)June 16, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's WhyJune 10, 2025 | marketbeat.comNVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialJune 6, 2025 | zacks.comWhat is Wedbush's Estimate for NovoCure FY2026 Earnings?June 5, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Sees Strong Trading Volume - Still a Buy?June 4, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsJune 4, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 8.2% - Should You Sell?June 3, 2025 | marketbeat.comResults From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingJune 2, 2025 | businesswire.comNovocure data support pancreatic cancer approval, says Wells FargoJune 2, 2025 | msn.comNovocure study shows improved pancreatic cancer survivalJune 2, 2025 | massdevice.comNovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer TrialJune 2, 2025 | aol.comAZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in NovoCure Limited (NASDAQ:NVCR)May 29, 2025 | marketbeat.com1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall StreetMay 28, 2025 | msn.comNovocure Announces Upcoming Investor EventsMay 27, 2025 | finance.yahoo.comNovoCure: Loading Up On Growth CatalystsMay 24, 2025 | seekingalpha.comNovoCure Limited: Profitability Remains ElusiveMay 21, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPEN, NVCR, LMAT, and ATRC Company DescriptionsApollo Endosurgery NASDAQ:APENApollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.AtriCure NASDAQ:ATRC$32.33 -0.55 (-1.67%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.LeMaitre Vascular NASDAQ:LMAT$82.98 +0.59 (+0.71%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$17.15 +0.05 (+0.28%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
